{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:05:13Z","timestamp":1787169913274,"version":"build-2736575974"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"\n A\n BSTRACT<\/jats:sc>\n <\/jats:title>\n \n Background:<\/jats:title>\n \n We investigated the pharmacokinetic behavior of pyrazinamide (PZA) and pyrazinoic acid (PA) in the presence of carbon-tetrachloride (CCl\n 4<\/jats:sub>\n ) plus antitubercular treatment (ATT) drug-induced liver injury (DILI) in rats.\n <\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n \n Thirty rats utilized in the experiment were separated equally into five groups. Each rat was injected with 0.5 ml\/kg CCl\n 4<\/jats:sub>\n intra-peritoneal injection on day zero. Group, I rats did receive only CCl\n 4<\/jats:sub>\n (single i.p. injection, 0.5 ml\/Kg in olive oil in a 1:1 ratio). Groups II, III, IV, and V did receive daily oral PZA, PZA plus isoniazid (INH), rifampicin (RMP) plus pyrazinamide (PZA), and three drugs together, respectively, for 21-days. Pharmacokinetic sampling was performed at 0, 0.5,1,3,6,12 and 24 hours post-dosing on day-20. Liver function test (LFT) was assessed at days 0,1,7, and 21 days after CCl\n 4<\/jats:sub>\n and ATT administration, and rats were sacrificed on the last experiment day.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n ATT treatment maintained the liver function changes initiated by CCl\n 4<\/jats:sub>\n administration. An evidential LFT rise was observed in groups administered with pyrazinamide. Co-administration of Isoniazid caused a 2.02 and 1.78 times increase in Area-under-the-curve (AUC) values of PZA and PA, respectively (p < 0.05). Histological and oxidative-stress changes supported the biochemical and pharmacokinetic observations.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n \n The enzyme inhibitory capacity of isoniazid is well-preservd in CCl\n 4<\/jats:sub>\n -induced liver injury.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/jpbs.jpbs_333_23","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T02:00:53Z","timestamp":1692151253000},"page":"146-151","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetic Assessment of Pyrazinamide and Pyrazinoic Acid in Carbon tetrachloride-induced Liver Injury Model in Wistar Rats"],"prefix":"10.4103","volume":"15","author":[{"given":"Swati","family":"Sharma","sequence":"first","affiliation":[{"name":"Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Taneja","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alka","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Anand","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dibyajyoti","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol N.","family":"Patil","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,8,15]]},"reference":[{"key":"R1-20240829","doi-asserted-by":"crossref","first-page":"e00226","DOI":"10.1128\/AAC.00226-17","article-title":"Lung tissue concentrations of pyrazinamide among patients with drug-resistant pulmonary tuberculosis","volume":"61","author":"Kempker","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R2-20240829","first-page":"225","article-title":"Therapeutic drug monitoring in the treatment of active tuberculosis","volume":"18","author":"Babalik","year":"2011","journal-title":"Can Respir J J Can Thorac Soc"},{"key":"R3-20240829","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/archdischild-2020-321426","article-title":"Pharmacokinetics and safety\/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis","volume":"107","author":"Ruslami","year":"2022","journal-title":"Arch Dis Child"},{"key":"R4-20240829","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000324904","article-title":"Chapter 17:Pharmacological considerations of antitubercular agents in children","volume":"40","author":"Goldman","year":"2011","journal-title":"Antituberc Chemother"},{"key":"R5-20240829","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1128\/AAC.01866-12","article-title":"A novel mechanism underlies the hepatotoxicity of pyrazinamide","volume":"57","author":"Shih","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R6-20240829","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3346\/jkms.2015.30.2.167","article-title":"Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels","volume":"30","author":"Jeong","year":"2015","journal-title":"J Korean Med Sci"},{"key":"R7-20240829","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/0960327117705426","article-title":"Metabolomics approach discriminates toxicity index of pyrazinamide and its metabolic products, pyrazinoic acid and 5-hydroxy pyrazinoic acid","volume":"37","author":"Rawat","year":"2018","journal-title":"Hum Exp Toxicol"},{"key":"R8-20240829","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1124\/dmd.121.000389","article-title":"Metabolism and hepatotoxicity of pyrazinamide, an antituberculosis drug","volume":"49","author":"Hussain","year":"2021","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"R9-20240829","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1086\/650576","article-title":"Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity","volume":"50","author":"Sharma","year":"2010","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"R10-20240829","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jceh.2012.12.001","article-title":"Hepatotoxicity related to anti-tuberculosis drugs:Mechanisms and management","volume":"3","author":"Ramappa","year":"2013","journal-title":"J Clin Exp Hepatol"},{"key":"R11-20240829","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.3748\/wjg.v20.i19.5760","article-title":"Antitubercular therapy in patients with cirrhosis:Challenges and options","volume":"20","author":"Kumar","year":"2014","journal-title":"World J Gastroenterol WJG"},{"key":"R12-20240829","doi-asserted-by":"crossref","first-page":"1044808","DOI":"10.3389\/fphar.2022.1044808","article-title":"Plasma metabolomic and lipidomic alterations associated with anti-tuberculosis drug-induced liver injury","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"R13-20240829","doi-asserted-by":"crossref","first-page":"1002126","DOI":"10.3389\/fimmu.2022.1002126","article-title":"Urine metabolomics and microbiome analyses reveal the mechanism of anti-tuberculosis drug-induced liver injury, as assessed for causality using the updated RUCAM:A prospective study","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"R14-20240829","doi-asserted-by":"crossref","first-page":"e20180254","DOI":"10.1590\/1806-3713\/e20180254","article-title":"Serum pyrazinamide concentrations in patients with pulmonary tuberculosis","volume":"45","author":"Lucena","year":"2019","journal-title":"J Bras Pneumol"},{"key":"R17-20240829","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1089\/jmf.2022.K.0153","article-title":"Scopoletin improves glucose homeostasis in the high-fructose high-fat diet-induced diabetes model in Wistar rats","volume":"26","author":"Batra","year":"2023","journal-title":"J Med Food"},{"key":"R18-20240829","doi-asserted-by":"crossref","first-page":"102939","DOI":"10.1016\/j.ajp.2021.102939","article-title":"Pharmacometabolomics-guided clozapine therapy in treatment resistant schizophrenia:Preliminary exploration of future too near","volume":"67","author":"Grover","year":"2022","journal-title":"Asian J Psychiatry"},{"key":"R19-20240829","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1080\/10428194.2022.2087067","article-title":"Post-transplant cyclophosphamide pharmacokinetics and haploidentical hematopoietic cell transplantation outcomes:An exploratory study","volume":"63","author":"Kasudhan","year":"2022","journal-title":"Leuk Lymphoma"}],"container-title":["Journal of Pharmacy and Bioallied Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.jpbs_333_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:14:52Z","timestamp":1787166892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.jpbs_333_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jpbs.jpbs_333_23","relation":{},"ISSN":["0976-4879","0975-7406"],"issn-type":[{"value":"0976-4879","type":"print"},{"value":"0975-7406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"2023-05-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}